uniQure (QURE) Competitors $61.59 +2.26 (+3.81%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. RDY, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, RVMD, VRNA, and RYTMShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), Qiagen (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Revolution Medicines (RVMD), Verona Pharma PLC American Depositary Share (VRNA), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors Dr. Reddy's Laboratories Viatris Roivant Sciences Qiagen Elanco Animal Health BridgeBio Pharma Moderna Revolution Medicines Verona Pharma PLC American Depositary Share Rhythm Pharmaceuticals uniQure (NASDAQ:QURE) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Do analysts prefer QURE or RDY? uniQure currently has a consensus target price of $71.75, suggesting a potential upside of 16.84%. Dr. Reddy's Laboratories has a consensus target price of $16.95, suggesting a potential upside of 15.66%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83 Is QURE or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to uniQure's net margin of -1,387.98%. Dr. Reddy's Laboratories' return on equity of 17.25% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,387.98% -1,010.74% -33.27% Dr. Reddy's Laboratories 16.99%17.25%11.63% Does the media refer more to QURE or RDY? In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Dr. Reddy's Laboratories and 0 mentions for uniQure. Dr. Reddy's Laboratories' average media sentiment score of 1.79 beat uniQure's score of 0.00 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Overall Sentiment uniQure Neutral Dr. Reddy's Laboratories Very Positive Do institutionals and insiders have more ownership in QURE or RDY? 78.8% of uniQure shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 4.8% of uniQure shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, QURE or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M124.25-$239.56M-$3.92-15.67Dr. Reddy's Laboratories$334.26B0.04$663M$0.6622.20 Which has more risk & volatility, QURE or RDY? uniQure has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. SummaryDr. Reddy's Laboratories beats uniQure on 9 of the 15 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.37B$3.42B$6.19B$10.78BDividend YieldN/A2.26%5.72%4.83%P/E Ratio-15.6823.5529.8828.59Price / Sales124.25270.54503.00189.86Price / CashN/A44.5736.5560.64Price / Book-438.6410.4212.026.62Net Income-$239.56M-$52.53M$3.32B$276.83M7 Day Performance5.88%2.08%1.63%2.10%1 Month Performance29.28%10.95%6.26%2.69%1 Year Performance847.69%13.94%61.43%34.06% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure2.297 of 5 stars$61.59+3.8%$71.75+16.5%+822.0%$3.39B$27.12M-15.74500Analyst ForecastGap UpRDYDr. Reddy's Laboratories2.9315 of 5 stars$14.44+1.5%$16.95+17.4%-6.5%$12.05B$3.81B21.8727,811News CoverageEarnings ReportVTRSViatris3.1715 of 5 stars$10.17+0.7%$11.17+9.8%-10.7%$11.86B$14.74B-3.5132,000Analyst ForecastROIVRoivant Sciences2.6639 of 5 stars$17.26+0.9%$19.94+15.5%+55.9%$11.79B$29.05M-24.66860QGENQiagen4.1331 of 5 stars$48.29+0.3%$49.69+2.9%+20.6%$10.73B$1.98B28.535,765Positive NewsELANElanco Animal Health2.7522 of 5 stars$21.42+4.4%$19.14-10.6%+74.0%$10.64B$4.44B24.919,000BBIOBridgeBio Pharma4.5052 of 5 stars$54.92-0.2%$65.06+18.5%+120.1%$10.50B$221.90M-13.43400Analyst ForecastMRNAModerna4.2527 of 5 stars$26.01-4.2%$39.93+53.5%-50.8%$10.16B$3.24B-3.455,800Trending NewsAnalyst ForecastRVMDRevolution Medicines4.3137 of 5 stars$54.10+8.9%$76.67+41.7%+10.2%$10.11B$11.58M-12.02250Analyst ForecastHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share1.0712 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRYTMRhythm Pharmaceuticals2.8678 of 5 stars$110.28-0.8%$107.21-2.8%+122.6%$7.32B$130.13M-36.64140 Related Companies and Tools Related Companies RDY Alternatives VTRS Alternatives ROIV Alternatives QGEN Alternatives ELAN Alternatives BBIO Alternatives MRNA Alternatives RVMD Alternatives VRNA Alternatives RYTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredTrump cannot stop this trainGallup reports that two-thirds of Americans now view socialism favorably — a shocking shift that one analyst s...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts